HilleVax Stock (NASDAQ:HLVX)

Forecast Ownership Financials Chart

Previous Close

$2.15

52W Range

$1.34 - $2.17

50D Avg

$1.99

200D Avg

$1.88

Market Cap

$106.80M

Avg Vol (3M)

$273.38K

Beta

0.76

Div Yield

-

HLVX Company Profile

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Apr 29, 2022

Website

HLVX Performance

HLVX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-155.29M	$-133.34M	$-65.11M
Net Income	$-147.27M	$-123.57M	$-257.00M
EBITDA	$-155.29M	$-132.47M	$-65.11M
Basic EPS	$-3.00	$-3.04	$-6.83
Diluted EPS	$-3.00	$-3.04	$-6.83

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
MOLN	Molecular Partners AG
NAMS	NewAmsterdam Pharma Company N.V.
GLUE	Monte Rosa Therapeutics, Inc.
TYRA	Tyra Biosciences, Inc.
VIGL	Vigil Neuroscience, Inc.
ANTX	AN2 Therapeutics, Inc.
PEPG	PepGen Inc.